Acromegaly Pipeline Analysis 2018: 10 Drugs Currently in Different Phases of Development

News provided by

Jun 01, 2018, 06:00 ET

DUBLIN, June 1, 2018 /PRNewswire/ --

The "Acromegaly Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.

Acromegaly Pipeline Analysis report covers more than 10 drugs currently in different phases of development

Acromegaly is a rare hormonal disorder where there is an excess amount of growth hormone (GH) in the human body leading to the formation of enlarged bone structure and children can grow to abnormal heights. Physical changes in a patient suffering from acromegaly are gradual and if not treated at the right time may be life-threatening as well. The disease usually affects the face, arms and legs.

The report provides acromegaly treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players.

Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Major industry players profiled as part of the report are Ionis Pharmaceuticals, Inc., Novartis AG, Aquestive Therapeutics, Peptron, and Ipsen among others.

Key Topics Covered:

1. Introduction
1.1. Research Methodology
1.2. Research Scope

2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities

5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling

Drug Name
Generic Name
Synonyms
Company
Collaborator
Route of administration
Target
Mechanism of Action
Technology
Molecule type
CAS Number
Weight
Chemical Formula
IUPAC name
ATC code

5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region

6. Company profiling

Ipsen
Novartis AG
Chiasma, Inc.
Strongbridge Biopharma plc
Aspireo Pharmaceuticals Limited
ITALFARMACO S.p.A.
CRINETICS PHARMACEUTICALS
Camurus AB
Amryt Pharma plc
Antisense Therapeutics Limited
Midatech Pharma PLC
TTY Biopharm
Foresee Pharmaceuticals Co., Ltd.
Bachem
Peptron
Aegis Therapeutics, LLC
Aquestive Therapeutics
Dauntless Pharmaceuticals
DexTech Medical AB
Ionis Pharmaceuticals, Inc.
leon-nanodrugs GmbH
Silence Therapeutics

For more information about this report visit https://www.researchandmarkets.com/research/7ss4zc/acromegaly?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets